179 related articles for article (PubMed ID: 10905597)
1. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C.
Guilera M; Forns X; Torras X; Enríquez J; Coll S; Solà R; Morillas R; Planas R; Ampurdanès S; Soler M; Costa J; Sáiz JC; Sánchez-Tapias JM; Rodés J
J Hepatol; 2000 Jul; 33(1):135-41. PubMed ID: 10905597
[TBL] [Abstract][Full Text] [Related]
2. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
3. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.
Pockros PJ; Tong M; Lee WM; van Leeuwen DJ; Keeffe EB; Bala K; Killenberg PG; Foust RT; Rosenblate HJ; Payne KM; Fromm H; Lesesne HR; Black M
J Viral Hepat; 1998 Jul; 5(4):271-6. PubMed ID: 9751014
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
[TBL] [Abstract][Full Text] [Related]
5. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
9. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group.
Chemello L; Cavalletto L; Bernardinello E; Boccato S; Casarin P; Cavinato F; Urban F; Pontisso P; Cecchetto A; Gatta A; Alberti A
J Viral Hepat; 1999 Jul; 6(4):321-7. PubMed ID: 10607247
[TBL] [Abstract][Full Text] [Related]
10. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
[TBL] [Abstract][Full Text] [Related]
11. Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
Bellobuono A; Mondazzi L; Tempini S; Chiodo F; Magliano E; Furione L; Idéo G
J Hepatol; 2000 Sep; 33(3):463-8. PubMed ID: 11020003
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
Brouwer JT; Hansen BE; Niesters HG; Schalm SW
J Hepatol; 1999 Feb; 30(2):192-8. PubMed ID: 10068095
[TBL] [Abstract][Full Text] [Related]
14. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
[TBL] [Abstract][Full Text] [Related]
15. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
[TBL] [Abstract][Full Text] [Related]
16. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
17. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
Niederau C; Strohmeyer G; Heintges T; Peter K; Göpfert E
Hepatogastroenterology; 1998; 45(21):797-804. PubMed ID: 9684137
[TBL] [Abstract][Full Text] [Related]
18. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
[TBL] [Abstract][Full Text] [Related]
19. Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients.
Fallows G; Kaita K; Minuk G; Penner F; Smart G; Dawood M; Rosser B
Can J Gastroenterol; 2000; 14 Suppl B():30B-35B. PubMed ID: 10938502
[TBL] [Abstract][Full Text] [Related]
20. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
